MAPK-ERK is a central pathway in T-cell acute lymphoblastic leukemia that drives steroid resistanceJordy C.G. van der Zwet, Jules P.P. Meijerink, Jelle Dylus et al.|Leukemia|2021Cited by 48
Comparative kinase and cancer cell panel profiling of kinase inhibitors approved for clinical use from 2018 to 2020Jeffrey J. Kooijman, Guido J.R. Zaman, Wilhelmina E. van Riel et al.|Frontiers in Oncology|2022Cited by 22
The Central Role of MAPK-ERK Signaling in IL7-Dependent and IL7-Independent Steroid Resistance Reveals a Broad Application of MEK-Inhibitors Compared to JAK1/2-Inhibition in T-ALLJordy C.G. van der Zwet, Jules P.P. Meijerink, Jessica G. C. A. M. Buijs-Gladdines et al.|Blood|2020Cited by 2